Tysabri

In the US, Tysabri (natalizumab systemic) is a member of the drug class selective immunosuppressants and is used to treat Crohn's Disease - Maintenance and Multiple Sclerosis.

US matches:

• Tysabri

UK matches:

• TYSABRI 300 mg concentrate for solution for infusion
• TYSABRI 300 mg concentrate for solution for infusion (SPC)

Ingredient matches for Tysabri

Natalizumab

Natalizumab is reported as an ingredient of Tysabri in the following countries:

• Australia


• Austria


• Belgium


• Canada


• Croatia (Hrvatska)


• Czech Republic


• Denmark


• Finland


• France


• Germany


• Ireland


• Italy


• Luxembourg


• Netherlands


• Norway


• Poland


• Slovakia


• Slovenia


• Spain


• Sweden


• Switzerland


• Tunisia


• United Kingdom


• United States

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.